Related Experiment Videos
Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot study
Alison Ehrlich1, Susan Booher, Yvonne Becerra
1Dermatology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Journal of the American Academy of Dermatology
|March 23, 2004
Summary
This study found that micellar paclitaxel effectively improved severe psoriasis in patients. The treatment showed therapeutic activity and was generally well-tolerated, suggesting potential for managing this chronic skin condition.
Area of Science:
- Dermatology
- Oncology
- Pharmacology
Background:
- Taxanes, such as paclitaxel, are known for their antiproliferative, antiangiogenic, and anti-inflammatory properties.
- Severe psoriasis is a chronic inflammatory skin condition with limited treatment options.
Purpose of the Study:
- To investigate the safety and efficacy of micellar paclitaxel in patients with severe psoriasis.
- To evaluate the therapeutic potential of a novel formulation of paclitaxel for dermatological conditions.
Main Methods:
- A Phase II, open-label, prospective pilot study involving 12 patients with severe psoriasis (PASI score ≥ 20).
- Patients received intravenous micellar paclitaxel in two stages with varying dosages and infusion intervals.
- The primary endpoint was the percentage change in Psoriasis Area and Severity Index (PASI) score from baseline to week 24 (Stage I) and week 20 (Stage II).
Main Results:
- All 5 patients in Stage I showed significant improvement, with a mean PASI decrease of 59.7%.
- In Stage II, all 4 completers demonstrated improvement, with a mean PASI decrease of 45.9%.
- Micellar paclitaxel was generally well-tolerated by the majority of participants.
Conclusions:
- Micellar paclitaxel exhibits significant therapeutic activity in managing severe psoriasis.
- The findings suggest that micellar paclitaxel is a promising treatment option for severe psoriasis.
- Further research is warranted to confirm these findings in larger patient cohorts.